Posaconazole-Model

Posaconazole PBPK

Repository files

Within this repository we share a whole body PBPK model of the azole antimycotic Posaconazole to model drug-drug-interactions (DDI) via CYP3A4. The model was verified using the GitHub Model of Midazolam from the OSP library.

For a detailed documentation of model development, quantitative model evaluation and sensitivity analysis, please refer to [1].

Code of conduct

Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.

Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.

License

The model code is distributed under the GPLv2 License.

References

[1] Gerner, B.; Aghai-Trommelschlaeger, F.; Kraus, S.; Grigoleit, G.U.; Zimmermann, S.; Kurlbaum, M.; Klinker, H.; Isberner, N.; Scherf-Clavel, O. A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients Pharmaceutics 2022, 14(12), 2556.